150 related articles for article (PubMed ID: 30573803)
21. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
Mudry P; Slaby O; Neradil J; Soukalova J; Melicharkova K; Rohleder O; Jezova M; Seehofnerova A; Michu E; Veselska R; Sterba J
BMC Cancer; 2017 Feb; 17(1):119. PubMed ID: 28183292
[TBL] [Abstract][Full Text] [Related]
22. Segmental overgrowth and aneurysms due to mosaic PDGFRB p.(Tyr562Cys).
Chenbhanich J; Hu Y; Hetts S; Cooke D; Dowd C; Devine P; ; Russell B; Kang SHL; Chang VY; Abla AA; Cornett P; Yeh I; Lee H; Martinez-Agosto JA; Frieden IJ; Shieh JT
Am J Med Genet A; 2021 May; 185(5):1430-1436. PubMed ID: 33683022
[TBL] [Abstract][Full Text] [Related]
23. Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet-derived growth factor receptor-beta.
Takenouchi T; Okuno H; Kosaki K
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):650-657. PubMed ID: 31710779
[TBL] [Abstract][Full Text] [Related]
24. Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG?
Linhares ND; Freire MC; Cardenas RG; Bahia M; Puzenat E; Aubin F; Pena SD
Genet Mol Res; 2014 Aug; 13(3):6287-92. PubMed ID: 25158255
[TBL] [Abstract][Full Text] [Related]
25. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
[TBL] [Abstract][Full Text] [Related]
26. Heterozygous PDGFRB Mutation in a Three-generation Family with Autosomal Dominant Infantile Myofibromatosis.
Lepelletier C; Al-Sarraj Y; Bodemer C; Shaath H; Fraitag S; Kambouris M; Hamel-Teillac D; El Shanti H; Hadj-Rabia S
Acta Derm Venereol; 2017 Jul; 97(7):858-859. PubMed ID: 28417142
[No Abstract] [Full Text] [Related]
27. Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.
Hettmer S; Dachy G; Seitz G; Agaimy A; Duncan C; Jongmans M; Hirsch S; Kventsel I; Kordes U; de Krijger RR; Metzler M; Michaeli O; Nemes K; Poluha A; Ripperger T; Russo A; Smetsers S; Sparber-Sauer M; Stutz E; Bourdeaut F; Kratz CP; Demoulin JB
Fam Cancer; 2021 Oct; 20(4):327-336. PubMed ID: 32888134
[TBL] [Abstract][Full Text] [Related]
28. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.
Martignetti JA; Tian L; Li D; Ramirez MC; Camacho-Vanegas O; Camacho SC; Guo Y; Zand DJ; Bernstein AM; Masur SK; Kim CE; Otieno FG; Hou C; Abdel-Magid N; Tweddale B; Metry D; Fournet JC; Papp E; McPherson EW; Zabel C; Vaksmann G; Morisot C; Keating B; Sleiman PM; Cleveland JA; Everman DB; Zackai E; Hakonarson H
Am J Hum Genet; 2013 Jun; 92(6):1001-7. PubMed ID: 23731542
[TBL] [Abstract][Full Text] [Related]
29. Infantile Myofibromatosis With Intracranial Extradural Involvement and PDGFRB Mutation: A Case Report and Review of the Literature.
Al Qawahmed R; Sawyer SL; Vassilyadi M; Qin W; Boycott KM; Michaud J
Pediatr Dev Pathol; 2019; 22(3):258-264. PubMed ID: 30103666
[TBL] [Abstract][Full Text] [Related]
30. A recurrent PDGFRB mutation causes familial infantile myofibromatosis.
Cheung YH; Gayden T; Campeau PM; LeDuc CA; Russo D; Nguyen VH; Guo J; Qi M; Guan Y; Albrecht S; Moroz B; Eldin KW; Lu JT; Schwartzentruber J; Malkin D; Berghuis AM; Emil S; Gibbs RA; Burk DL; Vanstone M; Lee BH; Orchard D; Boycott KM; Chung WK; Jabado N
Am J Hum Genet; 2013 Jun; 92(6):996-1000. PubMed ID: 23731537
[TBL] [Abstract][Full Text] [Related]
31. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis.
Lee JW
Clin Genet; 2013 Oct; 84(4):340-1. PubMed ID: 23865785
[No Abstract] [Full Text] [Related]
32. Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome.
Xu L; Jensen H; Johnston JJ; Di Maria E; Kloth K; Cristea I; Sapp JC; Darling TN; Huryn LA; Tranebjærg L; Cinotti E; Kubisch C; Rødahl E; Bruland O; Biesecker LG; Houge G; Bredrup C
Am J Hum Genet; 2018 Dec; 103(6):976-983. PubMed ID: 30449416
[TBL] [Abstract][Full Text] [Related]
33. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
34. Novel Oncogenic
Elsbernd A; Boulouadnine B; Ahmed A; Farooqi M; Sandritter T; Shakhnovich V; Blanding D; Demoulin JB; Thompson J
JCO Precis Oncol; 2022 Oct; 6():e2200250. PubMed ID: 36201717
[No Abstract] [Full Text] [Related]
35. Corneal Infantile Myofibromatosis Caused by Novel Activating Imatinib-Responsive Variants in
Howaldt A; Lenglez S; Velmans C; Schultheis AM; Clahsen T; Matthaei M; Kohlhase J; Vokuhl C; Büttner R; Netzer C; Demoulin JB; Cursiefen C
Ophthalmol Sci; 2024; 4(3):100444. PubMed ID: 38374928
[TBL] [Abstract][Full Text] [Related]
36. The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence.
Murray N; Hanna B; Graf N; Fu H; Mylène V; Campeau PM; Ronan A
Eur J Med Genet; 2017 Jul; 60(7):353-358. PubMed ID: 28286173
[TBL] [Abstract][Full Text] [Related]
37. [Autosomal dominant (familial) infantile myofibromatosis: The causative role of mutations in PDGFRB and NOTCH3].
Dereure O
Ann Dermatol Venereol; 2013 Dec; 140(12):833-4. PubMed ID: 24315235
[No Abstract] [Full Text] [Related]
38. [Sporadic infantile myofibromatosis: Mutations with PDGFRB gain-of-function].
Dereure O
Ann Dermatol Venereol; 2017; 144(8-9):574-575. PubMed ID: 28756885
[No Abstract] [Full Text] [Related]
39. Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications.
Foster A; Chalot B; Antoniadi T; Schaefer E; Keelagher R; Ryan G; Thomas Q; Philippe C; Bruel AL; Sorlin A; Thauvin-Robinet C; Bardou M; Luu M; Quenardelle V; Wolff V; Woodley J; Vabres P; Lim D; Igbokwe R; Joseph A; Walker H; Jester A; Ellenbogen J; Johnson D; Rooke B; Moss C; Cole T; Faivre L
Clin Genet; 2020 Jul; 98(1):19-31. PubMed ID: 32291752
[TBL] [Abstract][Full Text] [Related]
40. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
